203 related articles for article (PubMed ID: 21958851)
41. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.
Timmers HJ; Taieb D; Pacak K
Horm Metab Res; 2012 May; 44(5):367-72. PubMed ID: 22399235
[TBL] [Abstract][Full Text] [Related]
42. Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocytoma syndrome.
Levine DS; Metzger DL; Nadel HR; Oviedo A; Adam MJ; Skarsgard E
Pediatr Radiol; 2011 Oct; 41(10):1321-5. PubMed ID: 21567141
[TBL] [Abstract][Full Text] [Related]
43. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
44. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
45. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
Haug A; Auernhammer CJ; Wängler B; Tiling R; Schmidt G; Göke B; Bartenstein P; Pöpperl G
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):765-70. PubMed ID: 19137293
[TBL] [Abstract][Full Text] [Related]
46. Contrast- and non-contrast-enhanced ultrasonography (US) findings of hepatic metastasis from malignant pheochromocytoma/paraganglioma.
Nakano S; Tsushima Y; Higuchi T; Taketomi-Takahashi A; Amanuma M
Jpn J Radiol; 2012 May; 30(4):310-6. PubMed ID: 22271156
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
48. Quantitative
Amodru V; Guerin C; Delcourt S; Romanet P; Loundou A; Viana B; Brue T; Castinetti F; Sebag F; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):278-282. PubMed ID: 28918451
[TBL] [Abstract][Full Text] [Related]
49. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
[TBL] [Abstract][Full Text] [Related]
50. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Shamim SA; Kumar A; Kumar R
PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675
[TBL] [Abstract][Full Text] [Related]
51. Anatomical and functional imaging of tumors in animal models: focus on pheochromocytoma.
Martiniova L; Ohta S; Guion P; Schimel D; Lai EW; Klaunberg B; Jagoda E; Pacak K
Ann N Y Acad Sci; 2006 Aug; 1073():392-404. PubMed ID: 17102108
[TBL] [Abstract][Full Text] [Related]
52. Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [
Sun Y; Zhao N; Liu W; Liu M; Ju Z; Li J; Cheng Z; Liu X
Mol Imaging Biol; 2018 Oct; 20(5):771-779. PubMed ID: 29520623
[TBL] [Abstract][Full Text] [Related]
53. Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET.
Morana G; Piccardo A; Tortora D; Puntoni M; Severino M; Nozza P; Ravegnani M; Consales A; Mascelli S; Raso A; Cabria M; Verrico A; Milanaccio C; Rossi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2084-2093. PubMed ID: 28752225
[TBL] [Abstract][Full Text] [Related]
54. Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT.
Calabria F; Chiaravalloti A; Di Pietro B; Grasso C; Schillaci O
Nucl Med Commun; 2012 Jun; 33(6):563-70. PubMed ID: 22395034
[TBL] [Abstract][Full Text] [Related]
55. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
56. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
57. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
[TBL] [Abstract][Full Text] [Related]
58. 18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma.
Lugat A; Drui D; Mirallié E; Kraeber-Bodéré F; Ansquer C
Clin Nucl Med; 2019 Sep; 44(9):738-740. PubMed ID: 31306205
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
[TBL] [Abstract][Full Text] [Related]
60. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
